Delivery Order SPE2DR25D1104-SPE2DR26FK077
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,384.82 under a firm fixed price contract structure. This delivery order represents a competitive award with no set-aside designation and is scheduled for completion by September 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,078.57 with a firm fixed price structure. This is a competitively awarded, non-set-aside contract with an ultimate completion date of October 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,711.16 delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector units on September 5, 2025, with an ultimate completion date of September 8, 2025. This firm fixed-price contract represents a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The work will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units valued at $1,954.96. This is a firm fixed price delivery order with an ultimate completion date of August 21, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this...
- The Defense Logistics Agency awarded a delivery order valued at $6,914.68 to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This firm fixed-price delivery order, with an ultimate completion date of September 16, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,782.72 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies on September 2, 2025, with completion targeted for September 3, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a small-value transaction...
- The Defense Logistics Agency awarded a delivery order valued at $2,230.21 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector units on August 6, 2025, with completion targeted for August 7, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded procurement from AmerisourceBergen's existing pharmaceutical supply contract with DLA. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $2,440.29 with a firm fixed price. This is a non-set-aside, competitively awarded delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,731.01. This firm fixed-price delivery order, which is due for completion by August 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical...
- SPE2DR25D1104Indefinite Delivery Contract
- SPE2DR25D1104-SPE2DR26FK077Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,197.19 to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 21, 2025, with performance fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation, reflecting AmerisourceBergen's capability to compete successfully in the open market for federal pharmaceutical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The underlying IDC serves as a global pharmaceutical support vehicle enabling delivery of specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 10/20/25 |